Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #85

Abstract: The Children’s Oncology Group (COG) childhood cancer repository (www.CCcells.org), supported by ALSF, establishes, validates, and banks patient-derived cell lines (PDCLs) and patient-derived xenografts (PDXs) from childhood cancers. Viable tumor, blood, or bone marrow samples obtained under informed consent via COG protocols are sent to a centralized resource lab to establish PDCLs and PDXs. PDCLs/PDXs are validated by short tandem repeat assay to patient material, verified free of human and mouse pathogens, tumor type validated by biomarkers, and telomere maintenance mechanism assessed. The repository has available PDCLs/PDXs from 578/87 neuroblastomas, 16/20 leukemias, 7/5 lymphomas, 20/3 Ewing sarcomas, 13/3 soft tissue sarcomas. 32/1 retinoblastomas, 1/ 5 osteosarcomas, 2/5 Wilm’s tumors, and 11 PDCLs from brain tumors. Hypoxic culture conditions are used to establish PDCLs, enhancing success rates and minimizing selection against cells by hyperoxia. Cultures in hypoxia are more often able to generate a PDCL and low-passage PDCLs in hypoxia generate xenografts comparable in RNA expression and drug response profiles to PDXs. Neuroblastoma PDCLs and PDXs are being established from patients enrolled on COG phase III studies at diagnosis and from disease persisting or progressing during and after therapy to enable future studies comparing genomics and drug response of PDCLs and PDXs to patient data. To date 56 PDCLs and 19 PDXs have been established from patients on the ANBL1531 phase III trial and 41 PDCLs and 4 PDXs from 41 patients on the ANBL2131 phase III study. The repository distributes PDCLs and PDXs to > 700 laboratories in 30 countries.